SecurityWLL / Whiting Petroleum Corp. (966387102)
President & CEOHolly Bradley J
IndustryCrude Petroleum and Natural Gas
Institutional Owners45
Institutional Shares28,072,337 - 30.87%
Common Stock Shares Outstanding90,927,193 shares (as of 2018-03-31)
Institutional Value$ 487,446,000 USD
Related 966387AE2 / Whiting Petroleum 7% Guaranteed Notes 2/1/14
966387AK8 / Whiting Petroleum Corp. 1.25% Bond due 2020
966387AL6 / Whiting Petroleum Corp. 1.25% Bond due 2020-04-01
966387AU6 / Whiting Petroleum Corp. 1.25% Bond due 2020-06-05
966387AR3 / Whiting Petroleum Corp. 5.0% Bond due 2019-03-15
966387AS1 / Whiting Petroleum Corp. 5.75% Bond due 2021-03-15
966387AV4 / Whiting Petroleum Corp. 5.75% Bond due 2021-03-15
966387AT9 / Whiting Petroleum Corp. 6.25% Bond due 2023-04-01
966387AF9 / Whiting Petroleum Corp 6.50% 10/1/18
966387AQ5 / Whiting Petroleum Corp. 6.5% Bond due 2018-10-01

Institutional Stock Ownership and Shareholders()

WLL / Whiting Petroleum Corp. Institutional Ownership

Whiting Petroleum Corp. (NYSE:WLL) has 45 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 28,072,337 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., Numeric Investors Llc, BlackRock Fund Advisors, Edmond De Rothschild Asset Management (france), Perkins Investment Management, LLC, BlackRock Advisors LLC, Schneider Capital Management Corp, Top Ace Asset Management Ltd, BlackRock Group LTD, and New York State Common Retirement Fund.
Whiting Petroleum Corp. (NYSE:WLL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/wll"><img src="https://images.fintel.io/us-wll-so.png" alt="WLL / Whiting Petroleum Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 44,045 40,983 -6.95 243 224 -7.82
2017-05-16 13F-HR FIRST FINANCIAL EQUITY CORPORATION 30,239 280
2017-05-01 13F-HR Spot Trading L.L.C Put 84,000 795
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 6,300 0 -100.00 76 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 7,378,494 7,505,553 1.72 64,488 90,217 39.90
2017-02-06 13F-HR Top Ace Asset Management Ltd 148,903 1,000,000 571.58 1,301 12,020 823.90
2018-02-12 13F-HR Hutchin Hill Capital, LP 100,000 0 -100.00 546 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 1,485,877 2,264 17,860 688.87
2018-05-15 13F-HR Linden Advisors LP 425,775 225,775 -46.97 11,275 7,640 -32.24
2018-04-27 13F-HR ADAMS NATURAL RESOURCES FUND, INC. 62,875 62,875 0.00 1,665 2,128 27.81
2017-05-01 13F-HR Spot Trading L.L.C 0 38,513 0 364
2018-04-26 13F-HR INVESTMENT COUNSELORS OF MARYLAND LLC 479,190 479,409 0.05 12,689 16,223 27.85
2018-04-10 13F-HR NISA INVESTMENT ADVISORS L.L.C. 60,000 64,600 7.67 1,589 2,186 37.57
2018-04-27 13F-HR NORTH STAR ASSET MANAGEMENT INC 91,078 91,162 0.09 2,412 3,085 27.90
2017-01-23 13F-HR CenterStar Fund, LLC Put 12
2018-05-14 13F-HR IHT Wealth Management, LLC 313 313 0.00 9 10 11.11
2018-05-14 13F-HR SNOW CAPITAL MANAGEMENT LP 240,078 154,528 -35.63 6,357 5,229 -17.74
2018-05-15 13F-HR Paloma Partners Management Co 37,001 0 -100.00 980 0 -100.00
2017-10-26 13F-HR PRIVATE CAPITAL MANAGEMENT INC 25,000 25,000 0.00 138 137 -0.72
2018-05-11 13F-HR Quantbot Technologies LP 31,240 0 -100.00 827 0 -100.00
2017-02-10 13F-HR BlackRock Japan Co. Ltd 40,088 63,568 58.57 350 764 118.29
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 0 12,736 0 431
2018-04-18 13F-HR Integral Derivatives, LLC Put 8,725 0 -100.00 231 0 -100.00
2018-05-07 13F-HR Focused Wealth Management, Inc 0 6 0 0
2018-05-14 13F-HR SCHNEIDER CAPITAL MANAGEMENT CORP 1,434,108 1,183,210 -17.50 37,975 40,040 5.44
2018-05-15 13F-HR Syntal Capital Partners, LLC 0 6,665 0 225
2016-11-14 13F-HR Keane Capital Partners, LLC 40,000 0 -100.00 370 0 -100.00
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 187,824 624,510 232.50 4,974 21,133 324.87
2018-05-15 13F-HR BALYASNY ASSET MANAGEMENT LLC 1,485,107 0 -100.00 39,326 0 -100.00
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 1,882 1,883 0.05 50 64 28.00
2018-05-15 13F-HR Quantitative Investment Management, LLC 17,900 0 -100.00 473 0 -100.00
2017-07-27 13F-HR Spot Trading L.l.c. Call 33,600 185
2017-08-14 13F-HR NUMERIC INVESTORS LLC 1,838,300 4,835,600 163.05 17,390 26,644 53.21
2018-02-14 13F-HR NUMERIC INVESTORS LLC 9,335,300 0 -100.00 50,971 0 -100.00
2018-05-15 13F-HR Bank of New York Mellon Corp 405,079 423,061 4.44 10,726 14,318 33.49
2017-02-10 13F-HR BlackRock Fund Advisors 2,911,498 5.94 76 34,996 45,947.37
2018-05-16 13F-HR Private Capital Group, Llc 30 1
2018-02-02 13F-HR Texan Capital Management 31,400 7,685 -75.53 171 203 18.71
2018-05-15 13F-HR PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO 38,863 88,164 126.86 1,029 2,983 189.89
2018-05-02 13F-HR RHUMBLINE ADVISERS 87,709 88,960 1.43 2,323 3,010 29.57
2018-05-14 13F-HR Fine Capital Partners, L.P. 5,458,525 0 -100.00 144,542 0 -100.00
2018-05-03 13F-HR Hodges Capital Management Inc. 7,650 7,000 -8.50 203 237 16.75
2017-05-15 13F-HR Perkins Investment Management, LLC 3,335,198 1,766,495 -47.03 40,089 16,711 -58.32
2017-01-23 13F-HR KANALY TRUST CO 144 144 0.00 1 2 100.00
2018-04-18 13F-HR Integral Derivatives, LLC Call 18,550 0 -100.00 491 0 -100.00
2017-05-15 13F-HR R&F Capital Advisors LP 12,970 0 -100.00 156 0
2016-11-14 13F-HR EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) 1,906,100 2,299,600 20.64 17,650 20,099 13.88
2017-02-10 13F-HR BlackRock Investment Management, LLC 606,566 606,383 -0.03 5,301 7,289 37.50
2018-05-08 13F-HR Alambic Investment Management, L.P. 17,600 0 -100.00 466 0 -100.00
2018-05-03 13F-HR Cypress Capital Management LLC (WY) 22,100 0 -100.00 585 0 -100.00
2017-05-01 13F-HR Spot Trading L.L.C Call 109,200 1,033
2018-05-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 344,574 301,683 -12.45 9,124 10,209 11.89
2017-07-27 13F-HR Spot Trading L.l.c. 50,560 279
2018-04-05 13F-HR Edge Wealth Management LLC 15 15 0.00 1 1 0.00
2018-05-14 13F-HR Portolan Capital Management, LLC 609,094 617,086 1.31 16,129 20,882 29.47
2017-01-23 13F-HR CenterStar Fund, LLC Call 58
2017-04-07 13F-HR CT Financial Advisors LLC 1,000 1,000 0.00 12,020 9,460 -21.30
2018-05-22 13F-HR AMALGAMATED BANK 16,561 16,397 -0.99 439 555 26.42
2017-07-24 13F-HR Carl Domino Inc 19,000 33,000 73.68 180 182 1.11
2017-08-10 13F-HR Century Capital Management, LLC 45,126 0 -100.00 427 0 -100.00
2017-07-27 13F-HR Spot Trading L.l.c. Put 72,800 401
2018-05-15 13F-HR METROPOLITAN LIFE INSURANCE CO/NY 2,598 2,603 0.19 69 88,086 127,560.87
2017-08-08 13F-HR Airain ltd 56,222 0 -100.00 532 0 -100.00
2018-05-07 13F-HR Massey, Quick & Co., LLC 99 0 -100.00 3 0 -100.00
2018-05-11 13F-HR MACQUARIE GROUP LTD 3,725 0 -100.00 99 0 -100.00
2017-01-13 13F-HR MetLife Securities, Inc 5,714 26,498 363.74 50 319 538.00
2017-02-10 13F-HR BlackRock Group LTD 891,324 2,964 10,715 261.50
2018-05-14 13F-HR BROWN BROTHERS HARRIMAN & CO 146 146 0.00 4 5 25.00

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Is Whiting Petroleum (WLL) Stock a Solid Choice Right Now?

2018-06-18 zacks
One stock that might be an intriguing choice for investors right now is Whiting Petroleum Corporation (WLL - Free Report) . This is because this security in the Oil and Gas - Exploration and Production - United States space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective. (13-0)

Big Oil Stocks: Why Chevron (CVX) Is the Best Right Now

2018-06-13 zacks
Shares of Chevron Corporation (CVX - Free Report) , which has survived the worst oil crash in more than 50 years, now sit near 52-week highs. The blue-chip energy company is up more than 100% off its August 2015 lows and poised for further capital appreciation, riding on its healthy earnings growth prospects. (46-0)

Top Stock Reports for Chevron, Glaxo & T-Mobile

2018-06-13 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Glaxo (GSK) and T-Mobile (TMUS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (71-0)

Should PowerShares Russell 1000 Equal Weight Portfolio (EQAL) Be on Your Investing Radar?

2018-06-13 zacks
Launched on 12/23/2014, the PowerShares Russell 1000 Equal Weight Portfolio (EQAL - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Blend segment of the US equity market. (12-0)

CUSIP: 966387102